NF-kB signaling in the control of Hematopoiesis

NF-kB 信号传导在造血控制中的作用

基本信息

项目摘要

Project Summary: NF-κB signaling pathway is one of the most extensively studied and understood pathways, however, the physiological impact of augmented NF-κB signaling in hematopoiesis has not been understood. Despite many recent studies documenting constitutive activation of NF-κB in patients with hematological disorders, including AML and MDS, it is remains unclear if constitutive NF-κB signaling is sufficient and/or necessary for the onset of the disease. Recently, we have shown that lack of A20 (a negative regulator of NF-κB) in hematopoietic stem cells (HSCs) causes loss of quiescence and severe hematologic abnormalities, due to constitutive NF-κB activation. In an attempt to decipher the role of NF-κB in HSCs, directly , we engineered mice to constitutively activate NF-κB in HSCs. Our preliminary data indicate that HSC quiescence and pool were completely lost, and that increased NF-κB signal alone was sufficient to disturb the transcriptional regulatory circuits of HSCs. In the proposed research, we would like to decode the potential molecular mechanisms through which increased NF-κB signals affect HSC biology. Our hypothesis is that deregulated canonical NF-κB signals impair hematopoietic stem cell (HSC) quiescence and functions by altering signal transduction pathways, `transcription factor networks' and expression of pro-inflammatory cytokines. To test this hypothesis, we will use a combination of genetic, molecular cell biology and biochemical approaches. In specific aim 1, we will decipher the intrinsic mechanisms through which NF-κB affects HSC functions. In specific aim 2, we will unravel the extrinsic role of NF-κB in the control of HSCs. In specific aim 3, we would generate a novel humanized mouse model and decode the involvement of NF-κB signals in human HSC biology. We believe that the proposed research will provide key insights into the pathologic processes involving deregulated NF-κB signals, and will aid the development of newer and more successful therapies for human hematologic diseases that arise due to constitutive NF-κB activation.
项目摘要: NF-κB信号通路是最广泛的研究途径之一,并理解 但是,途径,增强NF-κB信号传导的物理影响 尚未理解造血。尽管最近有许多研究记录了 血液学疾病患者(包括AML)的NF-κB的组成型激活 和MDS,目前尚不清楚配置NF-κB信号是否足够和/或 疾病发作所必需的。最近,我们表明缺乏A20(a NF-κB的负调节剂)在造血干细胞(HSC)中导致丧失 由于组成型NF-κB激活,静止和严重的血液学异常。 为了使NF-κB在HSC中的作用中解密,我们将小鼠设计为 组成性激活HSC中的NF-κB。我们的初步数据表明HSC 静止和池完全丢失,仅增加NF-κB信号是 足以干扰HSC的转录调节回路。在提议中 研究,我们想解码潜在的分子机制 NF-κB信号的增加会影响HSC生物学。 我们的假设是,放松管制的规范NF-κB信号会损害造血 干细胞(HSC)静止和通过改变信号转导的功能 途径,“转录因子网络”和促炎的表达 细胞因子。为了检验该假设,我们将使用遗传,分子细胞的组合 生物学和生化方法。在特定的目标1中,我们将破译固有的 NF-κB影响HSC功能的机制。在特定的目标2中,我们将 揭示NF-κB在控制HSC中的外在作用。在特定的目标3中,我们会 生成一种新型的人性化小鼠模型并解码NF-κB的参与 人类HSC生物学中的信号。 我们认为,拟议的研究将为您提供关键的见解 病理过程涉及放大NF-κB信号,并将有助于发展 应得的新的,更成功的人类血液学疾病疗法 组织NF-κB激活。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chozha Vendan Rathinam其他文献

Chozha Vendan Rathinam的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chozha Vendan Rathinam', 18)}}的其他基金

NF-kB signaling in the control of Hematopoiesis
NF-kB 信号传导在造血控制中的作用
  • 批准号:
    10087951
  • 财政年份:
    2017
  • 资助金额:
    $ 38.58万
  • 项目类别:
GENETIC & MOLECULAR CONTROL OF E3 UBIQUITIN LIGASES IN STEM DIFFERENTIATION
基因
  • 批准号:
    8360045
  • 财政年份:
    2011
  • 资助金额:
    $ 38.58万
  • 项目类别:

相似海外基金

Targeting Menin in Acute Leukemia with Upregulated HOX Genes
通过上调 HOX 基因靶向急性白血病中的 Menin
  • 批准号:
    10655162
  • 财政年份:
    2023
  • 资助金额:
    $ 38.58万
  • 项目类别:
Preclinical Validation of Personalized Molecular Assays for Measurable Residual Disease Monitoring in Pediatric AML
用于儿科 AML 可测量残留疾病监测的个性化分子检测的临床前验证
  • 批准号:
    10643568
  • 财政年份:
    2023
  • 资助金额:
    $ 38.58万
  • 项目类别:
Fast-kinetics approaches to define direct gene-regulatory functions of MYB in leukemia
快速动力学方法定义 MYB 在白血病中的直接基因调控功能
  • 批准号:
    10644259
  • 财政年份:
    2023
  • 资助金额:
    $ 38.58万
  • 项目类别:
The roles of AP-1 pathway activation in NK cell development and exhaustion programming in AML
AP-1 通路激活在 NK 细胞发育和 AML 衰竭编程中的作用
  • 批准号:
    10751755
  • 财政年份:
    2023
  • 资助金额:
    $ 38.58万
  • 项目类别:
Exploiting the Metabolic Dependencies of Pediatric AML
利用儿科 AML 的代谢依赖性
  • 批准号:
    10664637
  • 财政年份:
    2023
  • 资助金额:
    $ 38.58万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了